We are a pharmaceutical company focused on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. Since our inception, we have collaborated with the world’s leading experts in kidney disease and leveraged our knowledge of pathogenic oxidative chemistries to build a strong portfolio of intellectual property and to advance the development of our drug candidates. In February 2016, due to the remaining trial costs, our cash position and condition of the capital markets, our Board of Directors made a decision to pause the clinical program of our product candidate oral Pyridorin® and retained MTS Health Partners, L.P. to act as our financial advisor in connection with our exploration of potential business alternatives. There can be no assurance that the process to identify and evaluate potential business alternatives will result in a successful alternative for our business. If no transactions with respect to potential business alternatives are identified and completed, our Board of Directors may decide to pursue a restructuring, which may include a reorganization or bankruptcy under Federal bankruptcy laws, or a dissolution, liquidation and/or winding up of our company.
Company profile
Ticker
NRXGQ
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NephroGenex Inc
SEC CIK
Corporate docs
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
24 May 17
8-K
Regulation FD Disclosure
19 May 17
8-K
Regulation FD Disclosure
11 May 17
8-K
Regulation FD Disclosure
21 Apr 17
8-K
Regulation FD Disclosure
20 Apr 17
8-K
Regulation FD Disclosure
24 Mar 17
8-K
Regulation FD Disclosure
15 Mar 17
8-K
Departure of Directors or Certain Officers
1 Mar 17
8-K
Regulation FD Disclosure
17 Feb 17
8-K
Regulation FD Disclosure
16 Feb 17
Latest ownership filings
SC 13G/A
NephroGenex, Inc.
14 Feb 17
SC 13D/A
NephroGenex, Inc.
14 Apr 16
SC 13G/A
NephroGenex, Inc.
12 Feb 16
SC 13G/A
NephroGenex, Inc.
20 Jan 16
4
Eugen Steiner
10 Dec 15
4
Pierre Legault
12 Nov 15
4
Jaikrishna Patel
12 Nov 15
4
John Hamill
12 Nov 15
4
J. Wesley Fox
1 Sep 15
4
Jaikrishna Patel
7 Aug 15
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|